<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>There are promising market opportunities in developing next-generation mesothelin-targeted immunotherapies, with potential applications across various cancers such as mesothelioma, ovarian, and pancreatic. These therapies offer a targeted approach due to mesothelin's overexpression in tumors and limited presence in normal tissues.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179371/pipeline-mesothelin-targeted-immunotherapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=qm7kst&amp;utm_campaign=2252391+-+Mesothelin-Targeted+Immunotherapies+Pipeline+Report+2026%3a+mesothelin-targeted+R%26D+Programs+by+R%26D+Phase+in+a+Tabular+Format+and+Profile+of+Mesothelin-targeted+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of Mesothelin-Targeted Immunotherapies">"Pipeline of Mesothelin-Targeted Immunotherapies"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about Mesothelin-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting mesothelin. The report lists mesothelin-targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of mesothelin-targeted immunotherapies by drug modality. Mesothelin, a 40 kD glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein, is overexpressed in many cancers, potentially involved in adhesion and metastasis. The well-known interacting partner of mesothelin is CA125/MUC16, a member of the mucin family of glycoproteins which is expressed in ovarian cancer and malignant mesothelioma Given the limited expression of mesothelin in normal tissues and overexpression in several tumor cells, mesothelin presents a desirable target for tumor-specific therapy. Mesothelin expression has been identified in approximately 30% of cancers, including mesothelioma, ovarian, pancreatic, gastric, and non-small cell lung tumors, uterine malignancies as well as cholangiocarcinoma. In high grade ovarian cancer, mesothelin is overexpressed in 75% to 80% of patients. Normal expression of mesothelin is on mesothelial cells lining pleura, peritoneum, and pericardium. Low expression may be found on some other tissues, but anti-mesothelin antibodies or antibody-toxin conjugates have not shown much toxicity. Although several first generation drug modalities used for targeting mesothelin eventually have failed in clinical studies, such as immunotoxins, thorium-targeted therapies, antibody-drug conjugates, chimeric antigen receptor T cells, natural killer cells as well as T-cell engaging antibodies, improved next generation versions of such drug modalities have been developed and are applied to novel immunotherapy candidates for mesothelin-expressing cancers. This report will be prepared on demand within one working day upon order placement. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179371/pipeline-mesothelin-targeted-immunotherapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=qm7kst&amp;utm_campaign=2252391+-+Mesothelin-Targeted+Immunotherapies+Pipeline+Report+2026%3a+mesothelin-targeted+R%26D+Programs+by+R%26D+Phase+in+a+Tabular+Format+and+Profile+of+Mesothelin-targeted+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/irbepc</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MTJlNDljNWQtMjQ4OC00Mjk1LTkwZTEtZjRmNzg1ZjQ4ODZiLTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Mesothelin-Targeted Immunotherapies Pipeline Report 2026: mesothelin-targeted R&D Programs by R&D Phase in a Tabular Format and Profile of Mesothelin-targeted Immunotherapies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn